← Human Trials & Peer-Reviewed Studies
Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial.
Plain-language guide to PMID 39816051 (2024): double-blind randomized controlled trial of C-Peptide in 70 patients.
Key Facts
- PMID
- 39816051
- Journal
- Narra J
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Putranto R et al. (11 authors)
- DOI
- 10.52225/narra.v4i3.1342
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of C-Peptide, published as a randomized controlled trial.
The aim of this study was to investigate the effects of cholecalciferol on depression in patients with T2DM, exploring its mechanisms by analyzing its impact on C-peptide, serotonin, and neurotrophin-3 levels.
Why It Was Studied
A double-blind, randomized, placebo-controlled clinical trial was conducted at Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from April 2021 to September 2022.
Between-group comparisons were made using independent Student t- tests and Mann-Whitney U tests.
Who Took Part
According to the abstract, 70 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got C-Peptide and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received C-Peptide.
Some patients received a placebo instead of C-Peptide, giving a reference point.
Depression was assessed using the Beck Depression Inventory-II (BDI-II) before and 12 weeks after the intervention.
The levels of C-peptide, serotonin, and neurotrophin-3 were measured at the end of the fourth week of intervention using the enzyme-linked immunosorbent assay (ELISA) method.
What Was Measured
Between-group comparisons were made using independent Student t- tests and Mann-Whitney U tests.
The subject headings attached to it are Diabetes Mellitus, Type 2, Cholecalciferol, C-Peptide, Depression, Neurotrophin 3, Serotonin and Dietary Supplements.
Author keywords: Type 2 diabetes mellitus, neurotrophin-3 and vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of C-Peptide in 70 patients.
The publication is from 2024 (Narra J), a journal based in Indonesia.
More context: the C-Peptide compound page, all human trials.
Our Notes on the Compound
C-Peptide: The 31-amino-acid fragment cut from proinsulin when insulin is made; it has been given as an investigational treatment in a few trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.